Paladin’s Impavido Could Set A Price Tag For Priority Review Vouchers
This article was originally published in The Pink Sheet Daily
Executive Summary
Approval of the leishmaniasis treatment by its December user fee date would give the Canadian sponsor a voucher for a priority review, which it is likely to sell to another company.